Búsqueda | Biblioteca Virtual en Salud

1.

Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A.

Smith, Mark P; Rupon, Jeremy; Wali, Yasser; Rimawi, Hala; Korth-Bradley, Joan; Smith, Lynne; Rendo, Pablo.

Haemophilia ; 26(5): e232-e235, 2020 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-32497363

2.

A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial.

Carcao, Manuel; Schiavulli, Michele; Kulkarni, Roshni; Rendo, Pablo; Foster, Meredith; Santagostino, Elena; Casiano, Sandra; Königs, Christoph.

Blood Adv ; 8(6): 1494-1503, 2024 Mar 26.

Artículo en Inglés | MEDLINE | ID: mdl-38266154

3.

Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onset.

Tortella, Bartholomew J; Carr, Marcus E; Rendo, Pablo; Korth-Bradley, Joan; Smith, Lynne M; Kavakli, Kaan.

Blood Coagul Fibrinolysis ; 32(3): 180-185, 2021 Apr 01.

Artículo en Inglés | MEDLINE | ID: mdl-33631774

4.

First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China.

Yang, Renchi; Wu, Runhui; Sun, Jing; Sun, Feifei; Rupon, Jeremy; Huard, Francois; Korth-Bradley, Joan M; Xu, Lihong; Luo, Binyu; Liu, Yingxue Cathy; Rendo, Pablo.

Medicine (Baltimore) ; 100(21): e26077, 2021 May 28.

Artículo en Inglés | MEDLINE | ID: mdl-34032739

5.

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies.

Yang, Renchi; Zhao, Yongqiang; Wang, Xuefeng; Sun, Jing; Wu, Runhui; Jin, Chenghao; Jin, Jie; Wu, Depei; Rendo, Pablo; Sun, Feifei; Rupon, Jeremy; Huard, Francois; Korth-Bradley, Joan M; Xu, Lihong; Luo, Binyu; Liu, Yingxue Cathy.

J Blood Med ; 11: 439-448, 2020.

Artículo en Inglés | MEDLINE | ID: mdl-33269010

6.

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.

Korth-Bradley, Joan; Rupon, Jeremy; Plotka, Anna; Charnigo, Robert; Rendo, Pablo.

Clin Transl Sci ; 11(3): 283-288, 2018 05.

Artículo en Inglés | MEDLINE | ID: mdl-29575770

7.

Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa.

Rendo, Pablo; Lamb, Janice; Smith, Lynne; Fuiman, Joanne; Korth-Bradley, Joan M.

Blood Coagul Fibrinolysis ; 29(1): 81-86, 2018 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-29135476

8.

Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B.

Hua, Baolai; Wu, Runhui; Sun, FeiFei; Luo, Binyu; Alvey, Christine; Labadie, Robert; Qu, Peng Roger; Korth-Bradley, Joan M; Rendo, Pablo.

Thromb Haemost ; 117(6): 1052-1057, 2017 06 02.

Artículo en Inglés | MEDLINE | ID: mdl-28331929

9.

Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.

Korth-Bradley, Joan M; Rendo, Pablo; Smith, Lynne; Altisent, Carmen.

Clin Ther ; 38(4): 936-44, 2016 04.

Artículo en Inglés | MEDLINE | ID: mdl-26969334

10.

Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities.

Rendo, Pablo; Smith, Lynne; Lee, Hsiao-Yu; Shafer, Frank.

Blood Coagul Fibrinolysis ; 26(8): 912-8, 2015 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-26196195

11.

Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.

Parra Lopez, Rafael; Nemes, Laszlo; Jimenez-Yuste, Victor; Rusen, Luminita; Cid, Ana R; Charnigo, Robert J; Baumann, James A; Smith, Lynne; Korth-Bradley, Joan M; Rendo, Pablo.

Thromb Haemost ; 114(4): 676-84, 2015 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-26293201

12.

[Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer]. / Variables predictivas de respuesta a la eritropoyetina recombinante humana en pacientes con anemia y cáncer.

Lastiri, José M; Specterman, Sergio R; Rendo, Pablo; Pallotta, María G; Varela, Mirta S; Goldstein, Sofía.

Medicina (B Aires) ; 62(1): 41-7, 2002.

Artículo en Español | MEDLINE | ID: mdl-11965849

13.

Factors that influence the bleeding phenotype in severe hemophilic patients.

Rendo, Pablo; Shafer, Frank; Korth-Bradley, Joan M; Sivamurthy, Krupa; Korin, Jorge.

Blood Coagul Fibrinolysis ; 24(7): 683-90, 2013 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-24056291

14.

The role of transfusion-transmitted virus in patients undergoing hemodialysis.

Valtuille, Rodolfo; Frankel, Fernando; Gómez, Federico; Moretto, Héctor; Fay, Fabián; Rendo, Pablo; Lef, Leonardo; Fernández, José.

J Clin Gastroenterol ; 34(1): 86-8, 2002 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-11743253

15.

Erythropoietin and preemies.

Donato, Hugo; Rendo, Pablo; Prudent, Luis; Vain, Néstor.

Pediatrics ; 110(6): 1253-5; author reply 1253-5, 2002 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-12462238

16.

Tratamiento de la anemia en pacientes en hemodiálisis crónica con dosis bajas de eritropoyetina recombinante asociada o no a andrógenos / Anemia treatment in patients in chronic hemodialysis with low dosis of recombinant eritropoyetin associated or not with androgens

Cusumano, Ana; Rendo, Pablo; Mascheroni, Claudio; Puentes, María Angélica; Sánchez Avalos, Julio.

Rev. nefrol. diál. traspl ; (41): 7-12, ago. 1996. graf

Artículo en Español | LILACS | ID: lil-253607

17.

Tratamiento de la anemia en pacientes en hemodiálisis crónica con dosis bajas de eritropoyetina recombinante asociada o no a andrógenos / Anemia treatment in patients in chronic hemodialysis with low dosis of recombinant eritropoyetin associated or not with androgens

Cusumano, Ana; Rendo, Pablo; Mascheroni, Claudio; Puentes, María Angélica; Sánchez Avalos, Julio.

Rev. nefrol. diálisis transpl ; (41): 7-12, ago. 1996. graf

Artículo en Español | BINACIS | ID: bin-123869

18.

Empleo de eritropoyetina recombinante humana en la anemia de la insuficiencia renal crónica / The use of recombinant-human erythropoietin in the anemia of chronic renal failure

Bisigniano, Liliana; Rendo, Pablo; Diaz, Azucena; Costa, Marina; Rubinstein, Marta; Sánchez Avalos, Julio; Turconi, Amalia.

Med. infant ; 1(4,n.esp): 190-194, jun. 1994. tab

Artículo en Español | LILACS | ID: lil-281712

19.

Virus de la hepatitis C en pacientes de una unidad de hemodiálisis / Hepatitis C-like viruses in patients in a hemodialysis unit

Valtuille, Rodolfo; Fernández, José Luis; del Pino, Noemí; Lef, Leonardo; Berridi, José; Moretto, Héctor; Rendo, Pablo.

Rev. nefrol. diál. traspl ; (42): 9-22, abr. 1997. tab, graf

Artículo en Español | LILACS | ID: lil-253603

20.

Virus de la hepatitis C en pacientes de una unidad de hemodiálisis / Hepatitis C-like viruses in patients in a hemodialysis unit

Valtuille, Rodolfo; Fernández, José Luis; del Pino, Noemí; Lef, Leonardo; Berridi, José; Moretto, Héctor; Rendo, Pablo.

Rev. nefrol. diálisis transpl ; (42): 9-22, abr. 1997. tab, graf

Artículo en Español | BINACIS | ID: bin-123873

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A.

A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial.

Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onset.

First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China.

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies.

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.

Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa.

Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B.

Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.

Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities.

Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.

[Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer]. / Variables predictivas de respuesta a la eritropoyetina recombinante humana en pacientes con anemia y cáncer.

Factors that influence the bleeding phenotype in severe hemophilic patients.

The role of transfusion-transmitted virus in patients undergoing hemodialysis.

Erythropoietin and preemies.

Tratamiento de la anemia en pacientes en hemodiálisis crónica con dosis bajas de eritropoyetina recombinante asociada o no a andrógenos / Anemia treatment in patients in chronic hemodialysis with low dosis of recombinant eritropoyetin associated or not with androgens

Tratamiento de la anemia en pacientes en hemodiálisis crónica con dosis bajas de eritropoyetina recombinante asociada o no a andrógenos / Anemia treatment in patients in chronic hemodialysis with low dosis of recombinant eritropoyetin associated or not with androgens

Empleo de eritropoyetina recombinante humana en la anemia de la insuficiencia renal crónica / The use of recombinant-human erythropoietin in the anemia of chronic renal failure

Virus de la hepatitis C en pacientes de una unidad de hemodiálisis / Hepatitis C-like viruses in patients in a hemodialysis unit

Virus de la hepatitis C en pacientes de una unidad de hemodiálisis / Hepatitis C-like viruses in patients in a hemodialysis unit